Published by Iain Gilbert on 7th September 2026
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer drug Etcamah (camizestrant), used alongside a CDK4/6 inhibitor, has been granted accelerated approval in the US for patients with a common form of advanced breast cancer who show signs of developing resistance to standard hormone therapy.